



**TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION  
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)**

Madrid, 14 June 2023

In compliance with the information duties provided for in article 227 of the Law 6/2023, of 17 March, on the Securities Markets and Investment Services, Laboratorios Farmacéuticos ROVI, S.A. (hereinafter, "**ROVI**" or the "**Company**") hereby discloses to the Spanish National Securities Market Commission the following

**OTHER RELEVANT INFORMATION**

- I.** The Ordinary General Shareholder's Meeting held today, 14 June 2023, on first call, has approved all the proposed resolutions submitted by the Board of Directors to its vote and summarized as follows:
1. Approval of the of the individual financial statements of the Company and of the consolidated financial statements of the Company with its subsidiaries, as well as of the individual management report of the Company and the consolidated management report of the Company with its subsidiaries, all for the financial year ended 31 December 2022.
  2. Approval of the statement of non-financial information included in the consolidated management report of the Company with its subsidiaries for the year ended 31 December 2022.
  3. Approval of the proposal for the application of the individual profit for the year ended 31 December 2022 and the proposal for the final dividend, which includes the payment of a fixed dividend of 1.2938 euros gross per share entitled to receive it. The abovementioned amount will be paid on 5 July 2023.
  4. Approval of the management work and performance of the Board of Directors during the year ended 31 December 2022.
  5. Composition of the Board of Directors: Ratification and/or re-election, if appropriate, of directors for the term determined in the bylaws.
    - 5.1. Approval of the re-election of Mr. Marcos Peña Pinto as external independent director for the term determined in the bylaws.
    - 5.2. Approval of the re-election of Mrs. Teresa Corzo Santamaría as external independent director for the term determined in the bylaws

6. Approval of the maximum annual remuneration of the members of the Board of Directors in their capacity as such for 2023.
7. Re-election of the auditors of the Company and its consolidated group for financial year 2023, KPMG Auditores, S.L.
8. Delegation of powers to formalise and register the resolutions adopted by the General Shareholders' Meeting and to carry out the mandatory filing of the financial statements.
9. Approval of the annual report on Directors' remuneration with an advisory vote.

The text of the resolutions approved by the General Shareholders Meeting and the outcome of the voting will be published on the Company's website within the next five days.

**II.** The Board of Directors of ROVI has agreed to re-elect Mr. Marcos Peña Pinto and Ms. Teresa Corzo Santamaría both as members of the Appointments and Remuneration Committee and of the Audit Committee for a term of four years.

**III.** The Audit Committee of ROVI has agreed to appoint Ms. Teresa Corzo Santamaría as Chairman of the Audit Committee to replace Mr. Marcos Peña Pinto, considering that his position as Chairman of this Committee expired on June 12, upon four years having elapsed from his initial appointment as Chairman.

Thus, these Committees shall henceforth have the following composition and positions:

- Appointments and Remuneration Committee:
  - Mrs. Fátima Báñez García (Chairperson, independent director)
  - Mr. Marcos Peña Pinto (Member, independent director)
  - Ms. Teresa Corzo Santamaría (Member, independent director).
- Audit Committee:
  - Ms. Teresa Corzo Santamaría (Chairperson, independent director).
  - Mr. Marcos Peña Pinto (Member, independent director)
  - Ms. Fátima Báñez García (Member, independent director)

Mr. Juan López-Belmonte Encina

Chairman of the Board of Directors and Chief Executive Officer (*Consejero Delegado*)  
Laboratorios Farmacéuticos ROVI, S.A.